Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 41 clinical trials
Acute Promyelocytic Leukemia 2006 (APL)

To assess the role of Arsenic trioxide and/or ATRA during consolidation course in APL. It is hoped that the investigational arms will further increase the event-free survival at 2 years

anthracyclines
idarubicin
arsenic
tretinoin
  • 13 views
  • 07 Nov, 2020
  • 1 location
An Open-Label Phase 3 Study to Examine the Long-Term Safety Tolerability and Efficacy of APL-130277 for the Acute Treatment of "OFF" Episodes in Patients With Parkinson's Disease

An Open-Label Phase 3 Study to Examine the Long-Term Safety, Tolerability and Efficacy of APL-130277 for the Acute Treatment of "OFF" Episodes in Patients With Parkinson's Disease

levodopa
mini-mental state examination
dopa
hoehn and yahr scale
carbidopa
  • 104 views
  • 02 Apr, 2020
  • 1 location
AIDA2000 - Risk-Adapted Therapy for Patients With Acute Promyelocytic Leukemia

In AIDA 2000 therapy of acute promyelocytic leukemia (APL) is given in a risk-adapted manner. Risk factors are age and white-blood-cell (WBC)-count at diagnosis. Induction therapy is done

consolidation therapy
methotrexate
induction therapy
mitoxantrone
tretinoin
  • 40 views
  • 07 Nov, 2020
  • 1 location
Single Agent Arsenic Trioxide in the Treatment of Newly Diagnosed Acute Promyelocytic Leukemia

There is very limited data on the use of arsenic trioxide in newly diagnosed patients with acute promyelocytic leukemia. The use of arsenic trioxide was limited to relapsed patients

remission
hepatic toxicity
arsenic
tretinoin
  • 76 views
  • 07 Nov, 2020
  • 8 locations
Study of NRX 195183 Therapy for Patients With Relapsed or Refractory Acute Promyelocytic Leukemia

The purpose of this study is to determine whether NRX 195183 is effective in the treatment of relapsed or refractory Acute Promyelocytic Leukemia

tretinoin
nrx 195183
arsenic
cytotoxic chemotherapy
  • 7 views
  • 07 Nov, 2020
  • 1 location
Prevention and Treatment of Differentiation Syndrome in Patients With Acute Promyelocytic Leukemia

With the introduction of all-trans-retinoic acid (ATRA) and arsenic,the outcome of patients with acute promyelocytic leukemia (APL)has been improved considerably over the last

  • 0 views
  • 24 Jan, 2021
  • 1 location
FLAG+Ida With G-CSF Priming for Patients Younger Than 60 Years With Resistant AML

myeloid leukemia other than acute promyelocytic leukemia

induction chemotherapy
colony stimulating factor
fludarabine
granulocyte colony stimulating factor
acute promyelocytic leukemia
  • 22 views
  • 07 Nov, 2020
  • 1 location
Fludarabine and Cytarabine as Continuous Infusion Plus G-CSF Priming for Elderly Patients With Resistant AML

myeloid leukemia other than acute promyelocytic leukemia - The feasibility will be evaluated in terms of toxicities, complete remission rate, duration of complete remission, disease

colony stimulating factor
fludarabine
granulocyte colony stimulating factor
acute promyelocytic leukemia
induction chemotherapy
  • 23 views
  • 07 Nov, 2020
  • 1 location
ATRA Trial - ACTIVITY OF ATRA IN COMBINATION WITH ANASTROZOLE IN PRE-OPERATIVE PHASE OF OPERABLE HR-POSITIVE/HER2-NEGATIVE EARLY BREAST CANCER eBC ATRA TRIAL

Promyelocytic Leukemia, APL) is well established, its use in solid tumors is limited. However, some recent pre-clinical evidence suggests a possible role of ATRA in the treatment of specific subtypes of HR

  • 0 views
  • 23 Jan, 2021
  • 1 location
Study for Patients With Newly Diagnosed High-risk Acute Promyelocytic Leukemia

Acute promyelocytic leukemia (APL) is a rare subtype of acute myeloid leukemia (AML) characterized by consistent clinical, morphologic, and genetic features. According to the FAB classification

consolidation therapy
methotrexate
acute promyelocytic leukemia
hysterectomy
mitoxantrone
  • 0 views
  • 23 Jan, 2021
  • 8 locations